Few cancer diagnoses arrive after as long a wait as a neuroendocrine tumour. Many people we speak to describe years of being told their flushing was the menopause, their diarrhoea was IBS, or their wheeze was asthma. They learn only much later that a tumour was behind it all. This page explains, for Ireland, how that delay happens and what a claim involves. It covers the point at which a late diagnosis stops being bad luck and becomes a cancer misdiagnosis claim. It is written to help you understand your position, not to give medical advice. You can arrange a confidential consultation with a personal injury solicitor in Dublin at any stage.

What a NET or carcinoid is, and why it is so often missed

A neuroendocrine tumour is a cancer of the hormone-producing cells found throughout the body. Neuroendocrine tumours most often arise in the digestive system, particularly the pancreas and small bowel, and in the lungs.^[2] The older word carcinoid is still used for many of these tumours, especially the slow-growing ones in the gut and lungs. Some NETs release hormones that cause a cluster of symptoms called carcinoid syndrome. This is part of why they are so easily mistaken for other illnesses.

Two features explain why these tumours are missed for so long. First, they are genuinely rare and frequently slow-growing, so they sit low on the list of things a busy clinician is considering. Second, and more important for a claim, their symptoms are non-specific and intermittent. Flushing, loose stools, abdominal pain, wheeze and fatigue are the daily bread of general practice, and almost always have an innocent cause. The clinical difficulty is real. The legal question is not whether a doctor should have guessed a rare cancer. It is whether a reasonable doctor, faced with symptoms that persisted, returned, or failed to fit their benign label, should have investigated further or referred on.

That distinction matters because rarity is often raised as a defence, which we address directly below. This page covers neuroendocrine tumours and carcinoid as a group. A NET in the pancreas is a minority of pancreatic tumours, and sits alongside the more common type covered on our pancreatic cancer misdiagnosis page. Medullary thyroid carcinoma is itself a neuroendocrine cancer, discussed with other thyroid cancers on our thyroid cancer misdiagnosis page.

The diagnostic odyssey: how a NET is misdiagnosed in Ireland

The single most important fact about neuroendocrine tumours, for anyone wondering whether their late diagnosis was negligent, is how long the delay usually is. Patients with carcinoid syndrome commonly wait five to seven years from their first symptoms to a correct diagnosis. A large proportion are found only once the cancer has already spread.^[4] A patient survey of people with NETs, published in the journal BMC Cancer, put the median time from first symptom to diagnosis at 53.8 months.^[5] Before that, 80 per cent of patients had visited their GP about the symptoms a median of 11 times. Around 30 per cent were diagnosed only after presenting acutely to A&E. The pattern is one of many appointments over years, not a single missed moment.

There is a structural reason this happens. It helps explain why a fair claim does not depend on blaming one individual for failing to recognise a rare cancer on sight. A full-time GP with a list of around 1,700 patients can expect to see roughly one new neuroendocrine tumour about every seven years.^[6] Set that against a patient seeing the same GP about recurring symptoms a median of 11 times, and a pattern emerges. No single clinician sees enough of these tumours to spot them quickly. The system relies instead on red-flag symptoms being recognised and acted upon as they recur. That is exactly why a NET claim turns on whether a documented, persisting pattern was investigated and referred, rather than on whether any one doctor "should have known." Where symptoms were dismissed repeatedly without examination, testing, or referral, the case for negligence strengthens. This is the same mechanism we describe more generally on our delayed cancer diagnosis page.

Which conditions NET symptoms are most often mistaken for

NET symptoms map onto a predictable set of wrong labels, and the label tends to follow the site of the tumour. The table below sets out the common misattributions and the red flag that should prompt a rethink. It is a guide to how delay happens, not a diagnostic tool.

The thread running through every row is persistence. A single innocent explanation for one episode is reasonable. The same explanation, repeated over months or years while the symptom continues, is the point a competent doctor is expected to look harder. It is also the point a claim examines closely. If the specific failure is not referring you for specialist assessment, see our page on failure to refer for urgent cancer investigation.

How neuroendocrine tumours are diagnosed in Ireland

Ireland has a defined pathway for these tumours, which matters to a claim because it sets the standard a delayed case is measured against. The national centre for neuroendocrine tumours is based at St Vincent's University Hospital in Dublin, designated by the National Cancer Control Programme. It is recognised as a European Neuroendocrine Tumour Society (ENETS) Centre of Excellence, and works with Mercy University Hospital in Cork and University Hospital Galway.^[2] The centre reviews new referrals from across the country through a specialist multidisciplinary team.^[7] One feature of the Irish system matters to a NET claim. The Rapid Access Clinics that fast-track suspected lung, prostate, breast and skin cancers do not cover neuroendocrine tumours, so there is no dedicated fast-track safety net to catch them.^[15] That places more weight on a GP or hospital doctor recognising and acting on the pattern through the ordinary referral route.

For scale, the National Cancer Registry recorded 1,927 invasive neuroendocrine tumours in Ireland between 1994 and 2010, an average of about 113 a year.^[8] Incidence has risen since. The blood test most associated with NETs is chromogranin A, a protein released by neuroendocrine cells, often paired with a urine 5-HIAA test where the tumour is producing hormones.^[13] Imaging then typically uses a gallium-68 DOTATATE PET scan, which detects the somatostatin receptors found on neuroendocrine cells. In a delayed-diagnosis claim, the breach often lies in the absence of any investigation. It can also lie in a failure to order the right specialist test, to act on an abnormal result, or to refer once the pattern was clear. Where the problem is an abnormal finding that was never followed up, see our page on red-flag symptoms not investigated.

How a NET is graded, and why that decides your claim

In short: neuroendocrine tumours are graded by how fast their cells divide, measured by the Ki-67 index. The grades are grade 1 (Ki-67 under 3 per cent), grade 2 (3 to 20 per cent) and grade 3 (over 20 per cent). Grade and stage at diagnosis drive survival. So the gap between where the cancer was when finally found and where it would have been if diagnosed on time is the heart of a delayed-diagnosis claim.

The grade matters because outcomes diverge sharply with it. In pooled data on digestive-system NETs, five-year survival was roughly 86 per cent for grade 1, 65 per cent for grade 2 and 25 per cent for grade 3.^[14] A NET that is slow-growing and curable when symptoms first appear can, over years of misattribution, climb in grade or spread to other organs. That change is what an oncology expert measures.

This is why a NET claim is built on records, not impressions. Your biopsy grade, your imaging, and your stage at the point of diagnosis are compared with what they would likely have been had the documented pattern been investigated sooner. The wider the gap, the clearer the harm. The same logic of comparing actual outcome against the avoidable one runs through every delayed cancer diagnosis claim.

When a delayed NET diagnosis becomes negligence

Not every late diagnosis is negligent. Irish law judges medical care by the standard set in Dunne v National Maternity Hospital [1989] IR 91.^[9] A doctor is negligent if they failed to do what a reasonable practitioner of equal status, acting with ordinary care, would have done. Applied to a NET, the question is not whether your GP or consultant should have named a rare cancer at the first visit. It is whether, on the information in front of them, a reasonable doctor would have investigated further or referred you sooner.

In practice, the failures that found a NET claim tend to fall into three groups:

• Failure to investigate: persistent symptoms treated as obviously benign, with no basic testing.
• Failure to refer: a pattern that warranted specialist assessment kept in primary care too long.
• Failure to act on results: an abnormal scan, blood marker or biopsy overlooked or not followed up.

Each is judged on independent expert evidence about what competent practice required at the time, not on the treating clinician's own account. Clinical guidelines inform that standard but do not replace it, a point the Irish courts have made clear on guideline adherence generally.

Proving the delay caused harm

Establishing that care fell short is only half of a claim. You also have to show that the delay caused harm, and in a slow-growing cancer this is usually the harder hurdle. The defence will often argue the tumour would have progressed the same way regardless of when it was found. This is frequently run as a tumour-doubling-time argument, built on growth-rate research such as the Peer paper of 1993. It is not the last word: in Crumlish v Health Service Executive [2023] IEHC 194, a delayed breast-cancer case involving Letterkenny University Hospital, the High Court rejected expert evidence that leaned solely on that paper. A NET claimant meets the argument by triangulating imaging, staging and grade rather than relying on a single dataset. That is the same ground covered on our parent page on cancer misdiagnosis claims.

Meeting that argument requires oncology evidence about how your particular tumour was likely to have behaved with earlier treatment. That includes whether earlier diagnosis would have meant less extensive surgery, gentler treatment, avoided complications such as carcinoid heart disease, or a better outlook. Carcinoid heart disease is worth naming on its own: prolonged untreated carcinoid syndrome can damage the heart valves, which is a separate, compensable injury beyond the cancer itself.

Irish law also recognises a related and important principle. In Philp v Ryan [2004] IESC 105 the Supreme Court compensated a patient whose prostate cancer diagnosis was delayed by eight months. That was so even though the evidence could not prove on the balance of probabilities that the delay had shortened his life. The court increased the award to €100,000 in total. It recognised that he had been wrongly deprived of the chance to consider his treatment in time, and had suffered real distress on learning of the delay.^[10] This is the doctrine of loss of chance. Its precise scope in Ireland remains unsettled, in particular whether a lost chance below fifty per cent is independently compensable for the physical outcome itself. A later Supreme Court decision, Quinn v Mid-Western Health Board [2005] IESC 19, reaffirmed the conventional but-for test for causation.^[11] Because it applies across cancer claims, our reference page on loss of chance explains the doctrine in full, including its interaction with reduced life expectancy.

What a claim may include

A delayed NET diagnosis is valued as a clinical-negligence personal injury claim, made up of two parts. General damages compensate for the pain, suffering and reduced quality of life caused by the avoidable progression of the cancer. They are assessed by reference to the Personal Injuries Guidelines 2021, which remain in force. A proposed 16.7 per cent increase to those figures was not enacted. The High Court confirmed in Somers v Commissioner of An Garda Síochána [2025] IEHC 388 that the original 2021 brackets continue to apply.^[1][12] Special damages compensate for financial losses you can prove, such as the cost of additional treatment, care and assistance, travel, and lost earnings. Unlike general damages, special damages are not capped, and in a serious cancer case they are often the larger part of the award.

Clinical negligence claims also differ procedurally from ordinary injury claims. Most personal injury claims in Ireland are first assessed by the Injuries Resolution Board. Medical negligence claims are exempt from that process and proceed instead through the courts. For a fuller picture of how the figures are built up, see our guide to cancer misdiagnosis compensation amounts. You can also read how a NET claim sits within the wider framework of a personal injury claim in Ireland.

Time limits and your date of knowledge

In Ireland you generally have two years less one day to start a claim. For a missed cancer, the clock usually runs not from the original appointment but from your date of knowledge. That is the date you first knew, or reasonably should have known, that your injury was significant and was connected to the care you received.^[3] Because a NET is so often hidden behind years of benign labels, the date of knowledge can fall much later than the symptoms began. That can be decisive in these cases. The rules on when the clock starts, and what can pause it, are set out on our page on the date of knowledge. Missing the deadline removes the right to pursue compensation regardless of how strong the claim is, so it is worth taking advice early.

Who can bring a claim

If you were the patient, you can bring the claim yourself. Because many neuroendocrine tumours are found only at an advanced stage, we are also often contacted by families. Where a death is suspected to have been contributed to by a missed or delayed diagnosis, their dependants and their estate may be able to bring a claim. The breach and causation questions are the same, but the heads of loss differ and the time limits are measured differently. We can explain how a fatal-injury claim works without any obligation.

Common questions